Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4103/0253-7613.182884 http://scihub22266oqcxt.onion/10.4103/0253-7613.182884 C4900003!4900003 !27298500     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27298500 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Indian+J+Pharmacol 2016 ; 48 (3 ): 292-7 Nephropedia Template TP {{tp|p=27298500 |t=2016. Weekly injection of histaglobulin produces long-term remission in chronic urticaria: A prospective clinical study |pdf=|usr=}}{{27298500 }} gab.com Text Weekly injection of histaglobulin produces long-term remission in chronic urticaria: A prospective clinical study JO: Indian J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=27298500 #FOAvip OBJECTIVE: Treatment of chronic urticaria (CU) can be difficult in many patients. Achieving long-term remission and reducing the requirement of antihistamines are vital in CU. The objective of this study was to assess the effectiveness of injection histaglobulin, a complex of histamine and human immunoglobulin, in producing relief in patients with CU. MATERIALS AND METHODS: Fifty-one patients with CU were enrolled into this prospective clinical study. Patients were administered 1 ml of injection histaglobulin subcutaneous for 8 consecutive weeks. They were also prescribed tablet levocetirizine 5 mg to be taken when required (but not more than the permitted dosage). Efficacy was assessed using urticaria activity score (UAS) which has a maximum score of 33/day, during each weekly visit. Final assessment was done after 24 weeks. RESULTS: Twenty-nine patients had completed the entire 8-week drug regimen. Mean basal UAS was 18.9 ± 6.3 and it reduced to 80.4% by 8 weeks. The angioedema sub-score reduced by 89.8%. Anti-histamine pill burden also reduced significantly. By 24 weeks of starting the therapy, 23 patients (45%) had attained complete remission. No adverse effects to the drug were observed. CONCLUSIONS: Histaglobulin was found to be effective in producing long-term remission and it reduced the antihistamine requirement as well. Thus, it can serve as an effective alternative to existing treatment modalities. Twit Text FOAVip Weekly injection of histaglobulin produces long-term remission in chronic urticaria: A prospective clinical study ????Indian J Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=27298500 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27298500 #FOAvip English Wikipedia <ref>{{Cite pmid|27298500 }}</ref> Weekly injection of histaglobulin produces long-term remission in chronic urticaria: A prospective clinical study #MMPMID27298500 Rajesh G ; Keerthi S ; Karthikeyan K ; Venkatesan M Indian J Pharmacol 2016[May]; 48 (3 ): 292-7 PMID27298500 show ga OBJECTIVE: Treatment of chronic urticaria (CU) can be difficult in many patients. Achieving long-term remission and reducing the requirement of antihistamines are vital in CU. The objective of this study was to assess the effectiveness of injection histaglobulin, a complex of histamine and human immunoglobulin, in producing relief in patients with CU. MATERIALS AND METHODS: Fifty-one patients with CU were enrolled into this prospective clinical study. Patients were administered 1 ml of injection histaglobulin subcutaneous for 8 consecutive weeks. They were also prescribed tablet levocetirizine 5 mg to be taken when required (but not more than the permitted dosage). Efficacy was assessed using urticaria activity score (UAS) which has a maximum score of 33/day, during each weekly visit. Final assessment was done after 24 weeks. RESULTS: Twenty-nine patients had completed the entire 8-week drug regimen. Mean basal UAS was 18.9 ± 6.3 and it reduced to 80.4% by 8 weeks. The angioedema sub-score reduced by 89.8%. Anti-histamine pill burden also reduced significantly. By 24 weeks of starting the therapy, 23 patients (45%) had attained complete remission. No adverse effects to the drug were observed. CONCLUSIONS: Histaglobulin was found to be effective in producing long-term remission and it reduced the antihistamine requirement as well. Thus, it can serve as an effective alternative to existing treatment modalities. |Adult [MESH] |Chronic Disease [MESH] |Drug Combinations [MESH] |Female [MESH] |Histamine/*administration & dosage [MESH] |Humans [MESH] |Male [MESH] |Middle Aged [MESH] |Prospective Studies [MESH] |Urticaria/*drug therapy [MESH]Weekly injection of histaglobulin produces long-term remission in chro(epmc).pdf DeepDyve Pubget Overpricing